Papoudou-Bai Alexandra, Koumpis Epameinondas, Karpathiou Georgia, Hatzimichael Eleftheria, Kanavaros Panagiotis
Department of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Department of Hematology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45500 Ioannina, Greece.
Diseases. 2024 Feb 29;12(3):51. doi: 10.3390/diseases12030051.
GATA3 is a transcription factor involved in T-cell maturation and has been previously shown to be aberrantly overexpressed in malignant Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). However, the immunophenotypes of the cell types expressing GATA3 have not been precisely characterized so far in cHL tissues. In this single-center retrospective cohort study we analyzed the expression patterns of GATA3 alone and in combination with B, T, NK or macrophage-associated markers in 73 cases with newly diagnosed cHL and investigated for a possible correlation with clinical and laboratory parameters. Immunohistochemistry (single and double) was performed using GATA3 alone and in combination with CD20, CD3, CD56, CD68, CD30 or CD15. Clinical and laboratory parameters were collected and correlated with the expression of GATA 3. GATA3 nuclear expression was found in HRS cells in 39/73 (54%) cases of cHL. The Nodular Sclerosis (NS) subtype showed the highest positivity rate (35/56, 63%), followed by mixed cellularity (MC; 4/14, 29%) and lymphocyte rich (LR; 0/3). Double immunostainings showed that GATA3 was expressed by CD30+ or CD15+ HRS cells and a few CD3+ T-cells, whereas GATA3 expression was not detected in CD20, CD56 or CD68+ cells. GATA3-negative cHL was significantly associated with unfavorable prognostic factors such as older age at diagnosis and increased levels of serum β2-microglobulin. The heterogenous expression patterns of GATA3 in HRS cells that were observed in a substantial proportion of cHL, mainly in the NS subtype, further support the biological heterogeneity of cHL.
GATA3是一种参与T细胞成熟的转录因子，先前已证明其在经典型霍奇金淋巴瘤（cHL）的恶性霍奇金和里德-斯腾伯格（HRS）细胞中异常过表达。然而，迄今为止，在cHL组织中表达GATA3的细胞类型的免疫表型尚未得到精确表征。在这项单中心回顾性队列研究中，我们分析了73例新诊断的cHL患者中GATA3单独以及与B、T、NK或巨噬细胞相关标志物联合的表达模式，并研究其与临床和实验室参数的可能相关性。使用单独的GATA3以及与CD20、CD3、CD56、CD68、CD30或CD15联合进行免疫组织化学（单染和双染）。收集临床和实验室参数并与GATA3的表达相关联。在73例cHL患者中，39例（54%）的HRS细胞中发现GATA3核表达。结节硬化（NS）亚型的阳性率最高（35/56，63%），其次是混合细胞型（MC；4/14，29%）和富于淋巴细胞型（LR；0/3）。双重免疫染色显示，GATA3由CD30+或CD15+HRS细胞以及少数CD3+T细胞表达，而在CD20、CD56或CD68+细胞中未检测到GATA3表达。GATA3阴性的cHL与不良预后因素显著相关，如诊断时年龄较大和血清β2-微球蛋白水平升高。在相当比例的cHL中观察到的HRS细胞中GATA3的异质性表达模式，主要在NS亚型中，进一步支持了cHL的生物学异质性。
